Single-Dose And Steady-State Bioavailability Comparisons

Why Compare Single-Dose and Steady-State Exposure?

Bioavailability can be assessed after one dose or after repeated dosing has reached steady state. These designs observe different concentration profiles: repeated doses produce accumulation, whereas a single dose does not. Yet, under specific pharmacokinetic assumptions, the total exposure attributable to one dose is the same as the exposure accumulated over one steady-state dosing interval. That connection makes it possible to compare availability estimates across designs—and to recognize when a difference points to violated assumptions or practical measurement problems.

The earlier material on dose-normalized AUC and absolute and relative bioavailability establishes how exposure ratios define these estimands. Here the focus is the relationship between the single-dose and steady-state versions of those comparisons. The equality is a result about the underlying exposure, not a claim that two estimates calculated from finite, noisy data must be numerically identical.

Definition: For a single dose \(D\), \(AUC_{0-\infty}\) is the area under the concentration–time curve from dosing to infinity. At steady state, \(AUC_{\tau}\) is the area under the concentration–time curve over one complete dosing interval of length \(\tau\). The dose-normalized exposures are \(AUC_{0-\infty}/D\) and \(AUC_{\tau}/D\), respectively. \(F\) denotes systemic bioavailability, the fraction of the administered dose that reaches systemic circulation, and \(CL\) denotes systemic clearance.

The Conditions Behind the Connection

For a single dose, the total amount reaching systemic circulation is \(FD\). If the drug is eventually eliminated, clearance is constant, and elimination is linear, the total amount eliminated is \(CL\) multiplied by the integrated concentration. Consequently, the single-dose exposure is \(FD/CL\). At steady state, the amount of drug in the body at the beginning and end of an interval is the same. If each interval supplies \(FD\) systemically, the amount eliminated during that interval is also \(FD\), giving the same expression for interval exposure.

AUC_{0-\infty}=\frac{FD}{CL} \qquad\text{and}\qquad AUC_{\tau}=\frac{FD}{CL}

The derivation requires more than simply giving multiple doses. It relies on approximately linear, time-invariant pharmacokinetics over the relevant concentration range: exposure scales proportionally with dose, and clearance and systemic availability do not change between single-dose and steady-state conditions. Absorption must be complete in the sense that the systemic input attributable to each dose is ultimately \(FD\). For the steady-state comparison, the subject must actually be at periodic steady state, and AUC must cover the full dosing interval.

Single dose.
With complete elimination after dosing, the total systemic input \(FD\) is balanced by total elimination, \(CL\int_0^\infty C(t)\,dt\). Equating the two gives \(AUC_{0-\infty}=FD/CL\).

Steady-state interval.
At periodic steady state, the amount of drug in the body at corresponding points in successive intervals is unchanged. The systemic input during an interval is \(FD\), so elimination during that interval is \(FD\) as well.

Convert elimination to exposure.
Under linear elimination with constant \(CL\), elimination over the interval is \(CL\int_0^\tau C(t)\,dt=CL\,AUC_\tau\). Thus \(AUC_\tau=FD/CL\), matching the single-dose expression.

This mass-balance argument does not require the concentration curve to have a particular shape or the body to follow a one-compartment model. It does require clearance to link elimination to concentration in the stated linear way. With nonlinear elimination, time-varying clearance, changing bioavailability, incomplete interval coverage, or failure to reach steady state, the argument may not hold.

Comparing Availability Estimates

For an absolute comparison, an extravascular product is compared with an intravenous reference. If both conditions involve the same drug and clearance is the same, the dose-normalized AUC ratio estimates the product’s absolute systemic availability. For a relative comparison, two formulations are compared; the corresponding ratio estimates their relative availability. The same ratio forms apply whether the AUCs come from single-dose or steady-state measurements.

F_{\text{absolute, single}} = \frac{AUC_{0-\infty,\text{extravascular}}/D_{\text{extravascular}}} {AUC_{0-\infty,\text{IV}}/D_{\text{IV}}} \qquad F_{\text{absolute, steady}} = \frac{AUC_{\tau,\text{extravascular}}/D_{\text{extravascular}}} {AUC_{\tau,\text{IV}}/D_{\text{IV}}}

F_{\text{relative, single}} = \frac{AUC_{0-\infty,\text{test}}/D_{\text{test}}} {AUC_{0-\infty,\text{reference}}/D_{\text{reference}}} \qquad F_{\text{relative, steady}} = \frac{AUC_{\tau,\text{test}}/D_{\text{test}}} {AUC_{\tau,\text{reference}}/D_{\text{reference}}}

These ratios estimate availability only when systemic clearance is common across the compared conditions. More generally, each dose-normalized AUC is \(F/CL\); a ratio therefore also reflects a clearance difference if clearance differs between conditions. Dose normalization accounts for unequal doses under proportional pharmacokinetics; it does not correct for nonlinear exposure or a changing clearance.

Worked Example: Absolute Availability at Single Dose and Steady State

In this hypothetical comparison, a person receives a 100 mg oral dose and a 50 mg IV dose in separate single-dose periods. The oral \(AUC_{0-\infty}\) is 18 mg·h/L, and the IV \(AUC_{0-\infty}\) is 12 mg·h/L. The dose-normalized exposures are:

\frac{18\ \text{mg·h/L}}{100\ \text{mg}} =0.1800\ \text{h/L}, \qquad \frac{12\ \text{mg·h/L}}{50\ \text{mg}} =0.2400\ \text{h/L}

The single-dose absolute availability estimate is \(0.1800/0.2400=0.7500\), or 75.0%. Now suppose that, at steady state with the same doses given once per 12-hour interval, the oral \(AUC_{\tau}\) is 18 mg·h/L and the IV \(AUC_{\tau}\) is 12 mg·h/L. Then:

\frac{18/100}{12/50} = \frac{0.1800\ \text{h/L}}{0.2400\ \text{h/L}} =0.7500

Both designs give an estimated absolute availability of 75.0%. This equality is consistent with the assumptions above; it is not evidence that every single-dose and steady-state dataset will yield exactly the same observed ratio.

Worked Example: Relative Availability With Unequal Doses

Consider hypothetical single-dose results for a test formulation at 200 mg and a reference formulation at 100 mg. Their \(AUC_{0-\infty}\) values are 36 and 18 mg·h/L. The relative availability estimate is:

\frac{36\ \text{mg·h/L}/200\ \text{mg}} {18\ \text{mg·h/L}/100\ \text{mg}} = \frac{0.1800\ \text{h/L}}{0.1800\ \text{h/L}} =1.000

Thus, the test formulation’s estimated dose-normalized exposure is equal to the reference’s in this example. Suppose the corresponding steady-state \(AUC_{\tau}\) values, measured over complete intervals, are 36 mg·h/L for the 200 mg test dose and 18 mg·h/L for the 100 mg reference dose. The steady-state calculation is likewise \((36/200)/(18/100)=1.000\). This dose-normalized comparison is interpretable only if exposure is proportional to dose and the formulations do not produce different clearance.

Accumulation Does Not, by Itself, Change Interval AUC

At steady state, concentrations can be higher than those observed after a single dose because drug from earlier doses remains in the body. That accumulation changes the concentration profile, including its peak and trough, but it does not invalidate the interval mass balance. Under the assumptions described above, the total exposure in one complete steady-state interval is still \(FD/CL\). AUC over several intervals would be larger because it covers more time; the relevant comparison is exposure over one interval against the single-dose exposure attributable to one dose.

The result concerns AUC, not every exposure measure. A steady-state maximum concentration need not equal a single-dose maximum concentration, and matching AUCs do not imply matching peak timing or peak height. AUC can support an availability comparison while other questions about the concentration profile require their own measures.

Worked Example: Investigating a Disagreement

Suppose hypothetical single-dose measurements give \(AUC_{0-\infty}=20\) mg·h/L for a 100 mg test dose and 25 mg·h/L for a 100 mg reference dose. The dose-normalized ratio is:

\frac{20/100}{25/100} =\frac{0.2000\ \text{h/L}}{0.2500\ \text{h/L}} =0.8000

At steady state, the corresponding complete-interval AUCs are 24 mg·h/L for the test and 15 mg·h/L for the reference, again at 100 mg per interval. The steady-state ratio is:

\frac{24/100}{15/100} =\frac{0.2400\ \text{h/L}}{0.1500\ \text{h/L}} =1.600

The two observed ratios differ substantially. If the underlying assumptions hold, their true dose-normalized ratios should agree. The discrepancy therefore warrants investigation; it does not, by itself, establish which estimate is correct or identify a cause. Check whether steady state was reached, whether each AUC covers the full interval, whether the single-dose terminal portion was adequately captured, whether doses and assay units were handled correctly, and whether dose-dependent or time-dependent pharmacokinetics could be present. Variability and uncertainty in the measurements also matter when deciding whether an observed difference is meaningful.

Diagnostics, Alternatives, and Limitations

A practical review should confirm that the comparison uses the intended dose and interval, that the steady-state sampling schedule represents a complete interval, and that the single-dose AUC includes the relevant exposure through its terminal phase. Examine whether dose-normalized exposures are plausibly proportional across the doses used and whether clearance or systemic availability could change with repeated administration. For example, an inducer or inhibitor introduced between study periods could alter clearance and make a ratio reflect more than availability.

Single-dose and steady-state designs are alternatives, not interchangeable measurements in every setting. Single-dose studies can avoid repeated dosing and provide \(AUC_{0-\infty}\), but require adequate characterization of the concentration decline and extrapolation when observations end before drug concentrations reach zero. Steady-state studies directly characterize a dosing interval relevant to a repeated regimen, but require sufficient dosing to reach steady state and reliable interval coverage. Neither design automatically resolves nonlinearity, time-varying pharmacokinetics, or condition-specific clearance.

Feature	Single-dose comparison	Steady-state comparison
Exposure quantity	\(AUC_{0-\infty}\) after one dose	\(AUC_{\tau}\) over one complete interval
Main design requirement	Capture and characterize the single-dose exposure	Reach periodic steady state and cover the interval
Under linear, time-invariant conditions	\(AUC_{0-\infty}/D=F/CL\)	\(AUC_{\tau}/D=F/CL\)
Important limitation	Terminal-phase estimation may affect total AUC	Failure to reach steady state or incomplete interval sampling can bias AUC

Common pitfall: “Concentrations accumulate at steady state, so the steady-state AUC for one dose must be larger than the single-dose AUC.” This confuses concentration at a given time with total exposure over a complete interval. Under linear, time-invariant pharmacokinetics, steady-state accumulation changes the profile, but mass balance gives \(AUC_{\tau}=FD/CL=AUC_{0-\infty}\) for the corresponding dose. Comparing an incomplete interval, or summing exposure over multiple intervals, does not make the same comparison.

Key takeaway: Single-dose \(AUC_{0-\infty}\) and steady-state \(AUC_{\tau}\) yield the same dose-normalized exposure, \(F/CL\), when systemic availability and clearance are stable, pharmacokinetics are linear, and the measurements cover the required exposure. Their ratios estimate the same availability comparison only when the compared conditions also share clearance.

Check Your Understanding

Answer each question, then compare your reasoning with the solutions below.

A drug has \(F=0.60\), \(D=150\) mg, and \(CL=5.0\) L/h. Under the stated assumptions, what are the expected single-dose \(AUC_{0-\infty}\) and steady-state \(AUC_{\tau}\) for that dose?
At steady state, a 100 mg test dose has \(AUC_{\tau}=24\) mg·h/L and a 200 mg reference dose has \(AUC_{\tau}=40\) mg·h/L. What is the relative dose-normalized exposure ratio?
Why can a steady-state concentration peak exceed the single-dose peak even when \(AUC_{\tau}\) equals \(AUC_{0-\infty}\)?
Name two conditions that could cause single-dose and steady-state dose-normalized AUC estimates to disagree beyond ordinary measurement variability.

Solutions. (1) \(FD/CL=(0.60)(150\ \text{mg})/(5.0\ \text{L/h})=18\ \text{mg·h/L}\). Both AUCs are 18 mg·h/L under the assumptions. (2) The ratio is \((24/100)/(40/200)=(0.2400\ \text{h/L})/(0.2000\ \text{h/L})=1.200\). The test has 1.200 times the reference’s dose-normalized interval exposure in this comparison. (3) Earlier doses contribute drug to the steady-state profile, which can raise the peak. AUC over one complete interval remains \(FD/CL\) by mass balance; peak concentration is not determined by AUC alone. (4) Examples include nonlinear or time-varying clearance, failure to reach steady state, incomplete steady-state interval coverage, or an inadequately characterized single-dose terminal phase.